Primary pulmonary hypertension and fenfluramine use

François Brenot, Philippe Herve, Patrick Petitpretz, Florence Parent, Pierre Duroux, Gérald Simonneau

Abstract
Not all the risk factors for primary pulmonary hypertension (PPH) are known. Appetite suppressants, including fenfluramine derivatives, are strongly suspected aetiological agents.

In a 5 year retrospective study fenfluramine use was evaluated among patients referred to a medical centre specialising in the management of PPH. Fifteen (20%) of 73 patients with PPH had used fenfluramine: all of them were women and in 10 (67%) there was a close temporal relation between fenfluramine use and the development of exertional dyspnoea. Initial right heart catheterisation in the 15 women showed severe resting pulmonary hypertension (mean (SD)) with pulmonary artery pressure (PAP) 57 (9) mm Hg, cardiac index 2-1 (0-5) l/min/m², and pulmonary vascular resistance (PVR) 29 (10) U/m². Short-term epoprostenol infusion produced a significant vasodilator response in 10 patients (mean fall in PVR 24 (15%) compared with control values). Three fenfluramine users with PPH showed spontaneous clinical and haemodynamic improvement: 3, 6 and 12 months after drug withdrawal but there was no significant difference in overall survival (transplant recipients excluded) between fenfluramine users and controls. Histological examination of lung tissue from five women who had used fenfluramine and 22 controls, with PPH showed features typical of advanced plexogenic pulmonary arteriopathy in all.

These results do not accord with earlier reports that PPH associated with fenfluramine is less severe and has a better outcome. Fenfluramine may be an aetiological agent that can precipitate or hasten the development of PPH. The results of a European case-control study should give new insights into risk factors for PPH and the cause and effect relation with fenfluramine.

Patients and methods
PATIENTS
Pulmonary hypertension was defined as a mean resting pulmonary artery pressure >25 mm Hg during right heart catheterisation, with a mean pulmonary wedge pressure below 12 mm Hg. Potential causes of secondary pulmonary hypertension were excluded on the basis of previously defined criteria. We excluded patients with PPH and concomitant portal hypertension or HIV infection (which may be another aetiologial agent in PPH).

Among other disease states and risk factors known to be associated with PPH we paid special attention to a history of the use of appetite suppressant drugs, especially fenfluramine derivatives (dl-fenfluramine or dexfenfluramine or both), and their effects on the clinical course of PPH (onset and worsening or improvement after withdrawal of the drug). At the time of first evaluation ever users of fenfluramine were classified as current or previous users: current users were those patients in whom symptoms suggestive of PPH had appeared or worsened during fenfluramine use; previous users were patients whose symptoms developed after fenfluramine use stopped and included “recent users” (whose symptoms occurred less than a year after the end of treatment) and “remote users” (whose symptoms began more than one year after the end of fenfluramine use).
Patients were routinely asked whether they had also used other appetite suppressant drugs (amphetamine derivatives).

**HAEMODYNAMIC MEASUREMENTS**

A complete set of baseline haemodynamic data was obtained for each patient, during right heart catheterisation performed with a 7F triple lumen flotation thermistor catheter (Edwards Swan-Ganz, Baxter Corporation). All measurements were made while patients were supine, breathing room air, and not taking vasodilating or inotropic drugs for at least 36-48 hours. Cardiac output was measured in triplicate by the thermodilution technique. The pulmonary vascular resistance index was calculated as the ratio of mean pulmonary artery pressure to cardiac index (cardiac output divided by body surface area). The heart rate was monitored continuously. Mean systemic artery pressure was measured with an external automatic sphygmomanometer (Dinamap Monitor, Critikon).

Most patients were tested with intravenous epoprostenol (prostacyclin, PGI₂), which is a potent pulmonary vasodilator used to detect the potential for pulmonary vasodilatation. The dose of epoprostenol (Fiolan, Wellcome) was increased by 2 ng/kg/min every 10 minutes from 5 ng/kg/min to a maximum dose of 10 ng/kg/min. The infusion was stopped immediately if systemic blood pressure dropped by more than 30% or if heart rate rose by more than 50% compared with control values and/or if side effects prevented a further increase in dosage. Significant dilatation during infusion was defined as a decrease in pulmonary vascular resistance (PVR) of at least 20% of the mean of 2 or 3 baseline measurements.

**STATISTICAL ANALYSIS**

Numerical results are expressed as means (SD) and ranges. Haemodynamic variables in patients in the fenfluramine and control groups were compared by the Wilcoxon rank sum test. The paired Student's t test was used for within-group comparisons of PVR before and during epoprostenol infusion. In fenfluramine users and in controls we estimated survival from first catheterisation in our hospital till the end of the follow up period (date of most recent information on the patient or death) by the Kaplan-Meier product-limit method. Lung or heart-lung transplant recipients were excluded from the survival analysis. Differences in mean survival time were tested by the log rank test. A value of p < 0.05 was regarded as statistically significant.

**Results**

Over a period of 60 months 105 patients with PPH were referred to our hospital for diagnostic and therapeutic evaluation (vasodilator testing or lung transplantation or both). Thirteen patients with associated portal hypertension and 19 with HIV infection were excluded. Fifteen of the 73 remaining PPH patients were ever users of fenfluramine and 58 had no history of fenfluramine use.

The 15 ever users of fenfluramine were all women (mean age 42 (10) range 20-54). All had used fenfluramine for at least three months (mean 15 (20), range 3-61 months) at the recommended dose of 30 mg per day for dexfenfluramine or 60 mg to 120 mg per day for dl-fenfluramine. Most ever users of fenfluramine (11/15) had taken dexfenfluramine (exclusively in eight) whereas three had used a combination of both derivatives. The four remaining patients had used only dl-fenfluramine.

Nine patients were regarded as current users at the time of diagnosis. Four complained of breathlessness while on fenfluramine therapy, which had been started 23 (21) months earlier. The five other current users, who developed dyspnoea on exertion 7 (4) months before fenfluramine use, became worse during treatment.

Four of the six patients regarded as previous users were "recent users" in whom symptoms developed less than one year after the end of treatment (1 to 11 months). Two other patients were remote users of fenfluramine and had stopped taking the drug 39 and 250 months before onset of PPH symptoms.

At the time of first evaluation in our hospital fenfluramine ever users had severe PPH (table 1) and most patients were in New York Heart Association functional class III or IV. For both groups, baseline haemodynamic findings showed severe precapillary pulmonary hypertension with decreased cardiac index at rest and an increase in pulmonary vascular resistance index up to six times greater than normal values (table 2). The effects of short-term infusion of epoprostenol in fenfluramine users were compared with those in the 53 of the 58 control patients (table 2): the proportion of responders to epoprostenol was higher in the fenfluramine group but not significantly. The level in the vasodilator response during challenge with epoprostenol was also similar in the two groups. No serious adverse events were reported.

Table 3 shows the outcome and follow up of fenfluramine users with PPH classified

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean(SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>42 (10)</td>
</tr>
<tr>
<td>Sex (f:m)</td>
<td>150*</td>
</tr>
<tr>
<td>PPH Symptoms:</td>
<td></td>
</tr>
<tr>
<td>Time between onset of symptoms and diagnosis (mnths)</td>
<td>20 (14)</td>
</tr>
<tr>
<td>Functional class (NYHA)</td>
<td></td>
</tr>
<tr>
<td>I or II (n (%))</td>
<td>5 (33)</td>
</tr>
<tr>
<td>III or IV (n (%))</td>
<td>10 (67)</td>
</tr>
<tr>
<td>Syncope or near-syncope (n (%))</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Chest pain (n (%))</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Haemoptysis (n (%))</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Right ventricular insuficiency (n (%))</td>
<td>5 (33)</td>
</tr>
<tr>
<td>Associated conditions:</td>
<td></td>
</tr>
<tr>
<td>Raynaud's phenomenon (n (%))</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Antinuclear antibody titre &gt;1/80 (n (%))</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Migraines (n (%))</td>
<td>3 (20)</td>
</tr>
</tbody>
</table>

according to the date of PPH diagnosis. Three of them (cases 1, 2, and 8) showed clinical and haemodynamic improvement after withdrawal of the drug. Two of these three patients (cases 1 and 2) had a history of long-term exposure to fenfluramine derivatives lasting 45 and 52 months respectively. They both were current fenfluramine users (for 42 and 40 months respectively) when they complained of exertional dyspnoea. In patient 1 catheterisation 6 months after withdrawal showed that PVR had fallen by more than 50% since the first catheterisation (from 24 to 10 U/m²). Her condition remained stable for two years but then worsened. She denied exposure to fenfluramine and she died of severe PPH while awaiting heart-lung transplantation. Patient 2 also showed a considerable spontaneous haemodynamic improvement 3 months after fenfluramine withdrawal, with a fall in PVR from 19 U/m² to 10 U/m². She is still doing well 4 years later, with moderate resting pulmonary hypertension and definitely abnormal haemodynamic function during exercise catheterisation. A third fenfluramine user (patient 8) also showed spontaneous improvement after drug withdrawal with a decrease in PVR from 35 U/m² to 15 U/m² between the initial catheterisation and one 12 months later. The remaining 12 patients showed either clinical and haemodynamic stabilisation or deterioration despite fenfluramine withdrawal.

Eight of the 15 fenfluramine users and 30 of the controls joined a lung or heart-lung transplantation waiting list. Two patients (10 and 13) had successful heart-lung transplantation and were excluded from survival analysis as were the 15 transplant recipients in the control group. There was no significant difference in overall survival (figure) between the fenfluramine users and the controls with about 55% and 42% survival respectively at 3 years. Histological studies were performed in five fenfluramine users (three necropsies, two heart and lung transplants). They showed features typical of advanced plexogenic pulmonary arteriopathy that resembled the pathologic findings in lung tissue obtained from 22/58 controls (seven necropsies, 15 heart and lung transplants).

Discussion

The issue of whether or not appetite suppressant use is associated with the development of PPH arose when the incidence of the disease suddenly and considerably increased in the 1960s in Western Europe. This epidemic was closely related to use of the appetite suppressant drug aminorex fumarate. Though laboratory animals did not develop pulmonary hypertension during chronic administration of aminorex, the cause-effect relation in humans was confirmed by epidemiological data. Since 1981 there have been 10 reports of cases of PPH associated with the use of the appetite suppressant drug fenfluramine.
the patients were women (aged 26–58). Most of the reported cases (8/10) were related to the use of dl-fenfluramine,5–10 whereas two other cases were linked to the more recently marketed dexfenfluramine.11,12

We report 15 additional cases of PPH in which fenfluramine may have influenced the expression and/or outcome of the disease. Though our series is much smaller than the 1960s PPH outbreak related to aminorex it raises the question of an association between fenfluramine exposure and PPH. In our series, the number of patients with PPH possibly related to fenfluramine use increased recently: two thirds of our cases were diagnosed between January 1991 and December 1992. This seems to parallel the increase in dexfenfluramine consumption in Europe.13 Because our hospital is a major referral centre for the management of PPH all our patients with PPH were referred for diagnosis and treatment and not because of fenfluramine exposure. The overall population of patients with PPH investigated in our institution over the past 4 years has remained stable at around 20 to 30 new cases per year. The proportion of fenfluramine users among current PPH patients was 20% of the overall patient population and 28% of all women (15/53). This rate is probably higher than the proportion of fenfluramine users among women of the same age in France.

Eight patients in this present series (four current and four recent users) developed exertional dyspnoea approximately 12 months after the start of treatment, a similar interval to that reported by Gurner at the time of the aminorex epidemic4,4 and to previous reports of fenfluramine-related PPH cases of which 6/10 were current or recent fenfluramine users when symptoms occurred.5–11 In the five remaining current users, who developed dyspnoea shortly before fenfluramine use, the influence of the drug seemed to be particularly obvious in two of them who definitely worsened after 2 months' exposure, with increased dyspnoea and near-syncpe on exertion. This suggests that fenfluramine may not only precipitate but may also hasten the course of the disease. A similar clinical course has already been reported in a patient with fenfluramine-related PPH who was rechallenged.5 The role of fenfluramine may be more questionable in the two remote users, though there are reports of two patients in whom symptoms developed 2 and 3 years respectively after fenfluramine use.6,8 Combination treatment with other appetite suppressants, which has been reported in series and individuals with appetite-suppressant-related PPH,5,14 was also noted in 6/15 of our fenfluramine users. In at least 10/15 (67%) fenfluramine ever users in the present series there seemed to be a close temporal relation between the period of use and the development of PPH, which was diagnosed shortly after onset or worsening of symptoms. As in all previously reported cases of PPH associated with fenfluramine use5–12 all our fenfluramine ever users were female. Though a female predominance is characteristic of PPH, the sex ratio reported in PPH related to appetite suppressants is much higher than the commonly reported 2:1 value in “pure” PPH.14 A likely explanation is that women are more likely than men to use appetite suppressants and are also believed to be more susceptible to pulmonary hypertension.5

In the Swiss epidemic the disease progressed more rapidly in the aminorex users than in the non-users and the mean time between onset of complaints and hospital admission was shorter.5–4 This was true of our fenfluramine users (20 (14) months) and non-users (31 (36) months) but the difference did not reach statistical significance (p = 0·37). Haemodynamic findings during baseline catheterisation showed severe pulmonary hypertension as did earlier studies of fenfluramine-related PPH.4,12 No relation has ever been found between the total duration of use of appetite suppressants and the degree of pulmonary hypertension,5 though there was no such relation in our patients. Two thirds of our patients showed a reversible component in pulmonary hypertension (vasodilatation in response to epoprostenol). The three fenfluramine users who showed spontaneous haemodynamic improvement after drug withdrawal showed the greatest vasodilatation in response to epoprostenol, with a decrease in PVR of approximately 45% of baseline values. These patients were current fenfluramine users at the time of diagnosis, and two of them had stopped taking the drug only a few days or weeks before catheterisation: thus their response to epoprostenol may have been measured when their pulmonary vascular tone was still increased by fenfluramine.

It has been suggested that patients with appetite-suppressant-related PPH have a better long-term course and survival than other patients with PPH.4,5 Five of the 10 cases of fenfluramine-related PPH reported here definitely showed spontaneous clinical and haemodynamic remission (partial or complete) within 1–3 months after first catheterisation and withdrawal of the drug.4,9,12 Better survival was also characteristic of the aminorex epidemic,4 though almost half died within the first 10 years of follow up.4 Half of the survivors were restudied several years after initial diagnosis and all showed a considerable increase in PVR during exercise catheterisation despite almost normal resting haemodynamic variables.4 This suggests persistence of underlying pulmonary arteriolar disease, as we found in our only fenfluramine user with a long lasting remission (case 2). Remission of PPH after drug withdrawal, however, was not the rule in most of the fenfluramine users we report and the idea of a better prognosis is not supported by their survival rate, which was not significantly better than that of the control PPH patients, who were evaluated and treated in the same manner and had comparable baseline clinical and haemodynamic characteristics.

The mechanisms responsible for pulmonary hypertension in patients using fenflu-
ramine or other amphetamine-related appetite suppressants are unclear. Most of these drugs, including fenfluramine, are structurally related and their anorectic activity is attributable to the phenylethylamine molecule. They all have sympathomimetic and serotoninergic effects to various degrees: the latter involve blocking of cellular uptake and metabolism of serotonin, inhibition of monoamine oxidase activity and, more generally, release of large amounts of serotonin from cellular stores (platelets, nerve endings). Serotonin contracts isolated pulmonary arteries in dogs and humans and has a synergic effect with platelet-derived growth factor on vascular smooth muscle cell proliferation. Moreover, humans with PPH had much higher concentrations of free plasma serotonin than controls. This finding is probably related to increased serotonin release from platelets. Furthermore, a recent study in rats showed that high doses of fenfluramine can induce acute lethal pulmonary hypertension.

Though this report of 15 new cases of PPH associated with fenfluramine use provides no definitive answers about a cause and effect relation, it suggests that fenfluramine influences the expression and outcome of primary pulmonary hypertension. The results of a long-term European case-control study should give new insights into the general risk factors for PPH development, including the relative risk associated with fenfluramine use.

We thank all respiratory physicians and cardiologists for referring patients; all nurses and other physicians of the department of pneumology and of the Paris Sud Lung Transplant Group; and Isabelle Peyrichou for preparing the typescript.